<DOC>
	<DOCNO>NCT02332811</DOCNO>
	<brief_summary>Primary Objective : Evaluate reduction serum phosphorus baseline end study Sevelamer carbonate tablet 800 mg Sevelamer carbonate Powder 2.4 g chronic kidney disease ( CKD ) patient haemodialysis dialysis Secondary Objective : Evaluate safety basis adverse event , change laboratory value vital sign baseline ( Day 0 ) Day 56 ( End treatment/ End Study )</brief_summary>
	<brief_title>An Open Label , Dose Titration Study Sevelamer Carbonate Tablets &amp; Powder Hyperphosphatemic CKD Patients</brief_title>
	<detailed_description>10 week include , 2 week wash-out period 8 week study treatment period</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Inclusion criterion : Men woman 18 year age old suffer CKD dialysis stable haemodialysis regimen If currently phosphate binder ( ) , willing stop enter 2 week washout period Willing avoid intentional change diet fast diet Have follow laboratory measurement : iPTH â‰¤ 1000 pg/mL screening ( include result obtain within 60 day prior screen ) If take phosphate binder , serum phosphorus measurement &gt; 5.5 mg/dL ( 1.78 mmol/L ) Screening ( Visit 1 ) . If take phosphate binder screening , serum phosphorus measurement &gt; 5.5 mg/dL ( 1.78 mmol/L ) twoweeks washout period Visit 1a ( Day 0 ) . Willing able take Sevelamer carbonate alone phosphate binder duration study Willing able avoid antacid phosphate binder contain aluminum , magnesium , calcium lanthanum duration study Willing able maintain screening dose vitamin D , and/or cinacalcet duration study , except safety reason If female childbearing potential ( premenopausal surgically sterile ) , willing use effective contraceptive method throughout study , include barrier method , hormone , intrauterine device For patient dialysis expect initiate dialysis duration study Signed inform consent Has participate investigational drug study within 30 day prior enrollment Level understand willingness cooperate visit procedure describe study personnel Exclusion criterion : Active dysphagia swallow disorder Predisposition current bowel obstruction , Severe gastrointestinal ( GI ) motility disorder include severe constipation Active ethanol drug abuse , exclude tobacco use Use antiarrhythmic antiseizure medication arrhythmia seizure disorder . In opinion investigator , patient poorly control diabetes mellitus , poorly control hypertension , active vasculitis , HIV infection , clinically significant unstable medical condition Planned renal transplant parathyroidectomy within 3 month Visit 1 Pregnant breastfeed Evidence active malignancy except basal cell carcinoma skin Unable comply requirement study Known hypersensitivity sevelamer constituent study drug Any condition , opinion investigator prohibit patient 's inclusion study The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>